To conduct a systematic review of the benefits and adverse events of cannabinoids for medical use, Dr Whiting and her team analysed twenty-eight databases from inception to April 2015.

Cannabinoids for medical use: a systemic review and meta-analysis

Utilizing multiple appropriate methods following guidance published by the Centre for Reviews and Dissemination and the Cochrane Collaboration, they came to the conclusions:

There was moderate-quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity. There was low-quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy, weight gain in HIV infection, sleep disorders, and Tourette syndrome. Cannabinoids were associated with an increased risk of short-term AEs.

Please access to the full review and analysis via the link below or read “Medicinal cannabis in Australia” if you would like to learn more about the topic.

Share this resource Got more questions?

Our friendly team members are here to help and guide you, answering any questions that you might have.

Contact us

Contact Us

For help or enquiries, please contact

Get in touch
with us online
Call us at
1800 819 775

Funded by Australian Government Department of Social Services. For more information visit DSS.GOV.AU